Your browser doesn't support javascript.
Author Correction: Robust SARS-CoV-2-specific T cell immunity is maintained at 6 months following primary infection.
Zuo, Jianmin; Dowell, Alexander C; Pearce, Hayden; Verma, Kriti; Long, Heather M; Begum, Jusnara; Aiano, Felicity; Amin-Chowdhury, Zahin; Hoschler, Katja; Brooks, Tim; Taylor, Stephen; Hewson, Jacqueline; Hallis, Bassam; Stapley, Lorrain; Borrow, Ray; Linley, Ezra; Ahmad, Shazaad; Parker, Ben; Horsley, Alex; Amirthalingam, Gayatri; Brown, Kevin; Ramsay, Mary E; Ladhani, Shamez; Moss, Paul.
  • Zuo J; Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK.
  • Dowell AC; Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK.
  • Pearce H; Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK.
  • Verma K; Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK.
  • Long HM; Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK.
  • Begum J; Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK.
  • Aiano F; Immunisation and Countermeasures Division, National Infection Service, London, UK.
  • Amin-Chowdhury Z; Immunisation and Countermeasures Division, National Infection Service, London, UK.
  • Hoschler K; Immunisation and Countermeasures Division, National Infection Service, London, UK.
  • Brooks T; Immunoassay Laboratory, National Infection Service, Porton Down, UK.
  • Taylor S; Immunoassay Laboratory, National Infection Service, Porton Down, UK.
  • Hewson J; Immunoassay Laboratory, National Infection Service, Porton Down, UK.
  • Hallis B; Immunoassay Laboratory, National Infection Service, Porton Down, UK.
  • Stapley L; Immunoassay Laboratory, National Infection Service, Porton Down, UK.
  • Borrow R; Sero-epidemiology Unit, Public Health England, Public Health Laboratory Manchester, Manchester Medical Microbiology Partnership, Manchester Royal Infirmary, Manchester, UK.
  • Linley E; Sero-epidemiology Unit, Public Health England, Public Health Laboratory Manchester, Manchester Medical Microbiology Partnership, Manchester Royal Infirmary, Manchester, UK.
  • Ahmad S; Department of Virology, Manchester Medical Microbiology Partnership, Manchester Foundation Trust, Manchester Academic Health Sciences Centre, Manchester, UK.
  • Parker B; The NIHR Manchester Clinical Research Facility, Manchester University NHS Foundation Trust, Manchester, UK.
  • Horsley A; Kellgren Centre for Rheumatology, NIHR Manchester Biomedical Research Centre, Manchester University NHS Foundation Trust, Manchester, UK.
  • Amirthalingam G; The NIHR Manchester Clinical Research Facility, Manchester University NHS Foundation Trust, Manchester, UK.
  • Brown K; Division of Infection, Immunity and Respiratory Medicine, University of Manchester, Manchester, UK.
  • Ramsay ME; Immunisation and Countermeasures Division, National Infection Service, London, UK.
  • Ladhani S; Immunisation and Countermeasures Division, National Infection Service, London, UK.
  • Moss P; Immunisation and Countermeasures Division, National Infection Service, London, UK.
Nat Immunol ; 22(7): 928, 2021 Jul.
Article in English | MEDLINE | ID: covidwho-1387433
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Language: English Journal: Nat Immunol Journal subject: Allergy and Immunology Year: 2021 Document Type: Article Affiliation country: S41590-021-00957-7

Similar

MEDLINE
LILACS
LIS
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Language: English Journal: Nat Immunol Journal subject: Allergy and Immunology Year: 2021 Document Type: Article Affiliation country: S41590-021-00957-7